Springworks initial data for myeloma study

 

• At the time of data cut-off, the objective response rate (ORR) of low-dose BLENREP plus nirogacestat across the DE and CE cohorts was 38%, with 17% of patients achieving a VGPR or better (N=24). The ORR of the BLENREP monotherapy control arm was 50%, with no patients achieving a VGPR or better (N=14).

https://www.globenewswire.com/news-release/2022/05/26/2451679/0/en/SpringWorks-Therapeutics-Highlights-Nirogacestat-Clinical-Data-at-the-2022-ASCO-Annual-Meeting.html